F. Errington

发表

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway

G. Nuovo, M. Coffey, K. Twigger, 2012, BMC Cancer.

Oncolytic Viruses: Do They Have a Role in Anti-Cancer Therapy?

F. Errington, A. Melcher, H. Pandha, 2008, Clinical medicine. Oncology.

Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy.

F. Errington, A. Melcher, R. Vile, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines

F. Errington, A. Melcher, R. Vile, 2003, Nature Medicine.

Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion.

Atique U. Ahmed, F. Errington, A. Melcher, 2002, Cancer research.

Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming

F. Errington, A. Melcher, R. Vile, 2006, Gene Therapy.

Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naïve T-cell priming

F. Errington, A. Melcher, R. Vile, 2005, British Journal of Cancer.

Oncolytic Reovirus Activity Following Tumor Cell Infection by Killer Cell Interactions Induce Antitumor Natural - Reciprocal Human Dendritic Cell

F. Errington, A. Melcher, R. Vile, 2009 .

Reciprocal Human Dendritic Cell–Natural Killer Cell Interactions Induce Antitumor Activity Following Tumor Cell Infection by Oncolytic Reovirus1

F. Errington, A. Melcher, R. Vile, 2009, The Journal of Immunology.

Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.

F. Errington, M. Tilby, B. Baguley, 1999, Molecular pharmacology.

Broad Antigenic Coverage Induced by Viral cDNA Library-based Vaccination Cures Established Tumors

F. Errington, A. Melcher, R. Vile, 2011, Nature Medicine.

Tumor Cells via CD 40 / CD 40 Ligand OK 432-Activated Human Dendritic Cells Kill

F. Errington, A. Melcher, P. Selby, 2008 .

sox30: a novel zebrafish sox gene expressed in a restricted manner at the midbrain-hindbrain boundary during neurogenesis

A. Ashworth, F. Errington, T. Jowett, 1999, Development Genes and Evolution.

Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming

M. Coffey, F. Errington, A. Melcher, 2011, Molecular Cancer.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

F. Errington, A. Melcher, R. Vile, 2009, Human gene therapy.

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity

M. Coffey, F. Errington, A. Melcher, 2009, Gene Therapy.

OK432-Activated Human Dendritic Cells Kill Tumor Cells via CD40/CD40 Ligand Interactions1

F. Errington, A. Melcher, P. Selby, 2008, The Journal of Immunology.

Synergistic Effects of Oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma

M. Coffey, R. Morgan, F. Errington, 2009, Clinical Cancer Research.

Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Oncolysis and Replication

F. Errington, A. Melcher, R. Vile, 2009, Clinical Cancer Research.

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

F. Errington, A. Melcher, R. Vile, 2008, Clinical Cancer Research.

Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial

M. Coffey, K. Twigger, F. Errington, 2008, Gene Therapy.

Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy

M. Coffey, K. Twigger, S. Bhide, 2008, Clinical Cancer Research.

The immune system--is it relevant to cancer development, progression and treatment?

F. Errington, A. Melcher, P. Selby, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

M. Coffey, K. Twigger, F. Errington, 2008, Gene Therapy.

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity1

M. Coffey, F. Errington, A. Melcher, 2008, The Journal of Immunology.

Oncolytic viruses: a novel form of immunotherapy

F. Errington, A. Melcher, R. Vile, 2008, Expert review of anticancer therapy.

Oncolytic viruses: a novel form

F. Errington, A. Melcher, R. Vile, 2008 .

Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.

F. Errington, M. Tilby, E. Willmore, 2002, Biochemical pharmacology.

Differences in the longevity of topo IIα and topo IIβ drug-stabilized cleavable complexes and the relationship to drug sensitivity

F. Errington, M. Tilby, E. Willmore, 2004, Cancer Chemotherapy and Pharmacology.

Full Title: Progress in Clinical Oncolytic Virus-based Therapy for Hepatocellular Carcinoma Article Type: Review

F. Errington, P. Selby, S. Griffin, 2015 .

Corrigendum: Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors

F. Errington, A. Melcher, R. Vile, 2012, Nature Medicine.

Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.

F. Errington, M. Tilby, E. Willmore, 2004, Cancer Chemotherapy and Pharmacology.